Hair Loss Treatment Is Stuck in the Past

For years, I’ve had the same conversation with patients sitting across from me. They’ve completed treatment. They’ve been told they’re “fine.” In some cases, they’ve even been told they’re in remission. And yet, they don’t feel restored. More often than not, the reason is visible: their hair never came back the same—or didn’t come back at all.

Medicine tends to define recovery in clinical terms. Patients define it differently. They’re looking for a return to normal—physically, emotionally, and socially. Hair loss sits squarely at the intersection of all three, and yet it remains one of the most under-addressed aspects of recovery.

That gap is becoming harder to ignore.

The Limits of a 30-Year-Old Solution

Topical minoxidil has been a mainstay in hair loss treatment for decades. It remains widely recommended, and in controlled settings, it can be effective. But clinical efficacy and real-world outcomes are not the same thing.

Patients are asked to apply it daily, indefinitely. It interferes with routine, can irritate the scalp, and often becomes one more obligation in an already demanding health regimen. Unsurprisingly, many stop using it long before meaningful results can occur.

Even among compliant patients, results are inconsistent. Absorption varies. Some areas respond, others don’t. From a physician’s standpoint, it’s difficult to predict who will benefit and to what degree.

We’ve accepted these limitations for a long time. Patients, increasingly, are not.

Why Oral Minoxidil Is Gaining Momentum

Low-dose oral minoxidil is now entering the conversation in a more serious way. The rationale is simple: if topical delivery is inconsistent, systemic delivery may offer a more reliable alternative. As a vasodilator, minoxidil increases blood flow and may help prolong the growth phase of hair follicles. Delivered orally, it reaches follicles uniformly rather than selectively.

From a patient perspective, the appeal is immediate. A once-daily pill is easier to manage, easier to remember, and easier to sustain. In clinical practice, convenience is not a minor factor—it often determines whether a treatment succeeds or fails.

A Shift in Risk, Not Just Delivery

That said, oral minoxidil is not simply a more convenient version of the same therapy. It represents a different category of intervention. Because it acts systemically, it carries systemic considerations: fluid retention, cardiovascular effects, and unintended hair growth in other areas. While low-dose protocols appear promising, long-term data in otherwise healthy populations is still developing.

This is where the current system shows strain. Physicians are using a drug off-label that many believe in—but without the standardized guidelines or large-scale data that typically support widespread adoption. In other words, practice is moving faster than policy.

The Larger Problem: Maintenance vs. Restoration

What oral minoxidil really exposes is a broader issue in how we approach hair loss. Most existing treatments are designed to slow decline. Few are designed to reverse it.

Dermatology has built effective frameworks around finasteride, minoxidil, and procedural options like platelet-rich plasma. But for many patients, especially those recovering from medical stressors like chemotherapy or hormonal disruption, these approaches plateau. They maintain what remains—but they don’t rebuild what’s been lost. Patients notice that distinction, even if medicine has been slower to address it.

The Case for Regenerative Approaches

This is where regenerative medicine is beginning to change the conversation. In my own clinical work, I’ve seen increasing promise in therapies involving amniotic-derived mesenchymal stem cells. Unlike adult-derived cells from adipose tissue or bone marrow, these cells are biologically more active—carrying a high concentration of growth factors and signaling molecules that support tissue repair.

The goal is not simply to stimulate hair follicles, but to improve the environment those follicles depend on. When inflammation is reduced and cellular signaling is restored, follicles that appeared inactive can, in some cases, become productive again.

That’s a fundamentally different objective than maintenance. It moves closer to true restoration.

What Regulators and Industry Should Be Watching

If oral minoxidil is to move beyond niche use, the path forward is clear: formal validation.

That means:

defined dosing standards
long-term safety data
clearer patient selection criteria

More broadly, it means recognizing that hair loss is not merely cosmetic. For patients recovering from illness, it can be one of the final markers of incomplete recovery. The healthcare system has been slow to expand its definition of what “recovered” looks like. That will likely need to change.

Patients Are Driving the Shift

What’s notable is that patients are already ahead of the system. They are more informed, more proactive, and less willing to accept treatments that are inconvenient, inconsistent, or incomplete. They are asking better questions—and expecting better answers. They are not just looking to slow hair loss. They are looking to restore what they’ve lost.

The Future Will Be Combined, Not Singular

Oral minoxidil is not the end of the story. It is part of a broader transition. The future of hair restoration will likely be multimodal—combining systemic therapies, regenerative medicine, and procedural interventions in ways that are tailored to the individual.

What’s changing is not just the treatment options. It’s the expectation. For the first time in decades, we are beginning to move beyond managing hair loss—and toward meaningfully reversing it.

Dr. Keith Kantor, PhD, ND, Trichologist
Clinical Director
Regentherapeutics
6065 Roswell Road, Suite 580
Sandy Springs, GA 30328